|
1) Baselga J, Averbuch SD. Zd1839 ‘iressa'as an anticancer agent. Drugs. 2000; 60(Suppl 1): 33-40. discussion 41-32
|
|
|
|
2) Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39
|
|
|
|
|
3) Paez JG, Janne PA, Lee JC, et al. Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500
|
|
|
|
|
|
4) Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing egfr mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163-7
|
|
|
|
|
|
5) Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 2004; 64: 8919-23
|
|
|
|
|
|
6) Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet. 2005; 366: 1527-37
|
|
|
|
|
|
7) Asahina H, Yamazaki K, Kinoshita I, et al. A phase ii trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95: 998-1004
|
|
|
|
|
|
8) Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase ii study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006; 24: 3340-6
|
|
|
|
|
|
9) Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid pcr clamp. Br J Cancer. 2006; 95: 1483-9
|
|
|
|
|
|
10) Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase ii prospective study of the efficacy of gefitinib for the treatment of stage iii/iv non-small cell lung cancer with egfr mutations, irrespective of previous chemotherapy. Lung Cancer. 2007; 56: 383-9
|
|
|
|
|
|
11) Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid pcr clamp. Cancer Res. 2005; 65: 7276-82
|
|
|
|
|
|
12) Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene t790m mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006; 66: 7854-8
|
|
|
|
|
|
13) Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 2007; 98: 246-52
|
|
|
|
|
14) Miyazawa H, Tanaka T, Nagai Y, et al. PNA-LNA PCR clamp-based detection test for gefitinib-refractory T790M EGFR mutation. Cancer Sci. in press
|
|
|
|
|